Should a menopausal patient with genitourinary symptoms stop her low‑dose combined oral contraceptive Lo Loestrin Fe (ethinyl estradiol/norethindrone acetate) because her husband is sterilized?

Should Your Patient Discontinue Lo Loestrin Fe?

No—your patient should not discontinue Lo Loestrin Fe solely because her husband has been sterilized. The combined oral contraceptive (COC) she is taking provides therapeutic benefits beyond contraception that are highly relevant to managing her genitourinary symptoms of menopause, and abrupt discontinuation would eliminate these benefits without addressing her underlying condition.

---

Why Continuing Lo Loestrin Fe Is Appropriate

Therapeutic Role Beyond Contraception

• Lo Loestrin Fe contains norethindrone acetate (1 mg) and ethinyl estradiol (10–20 mcg), which function as low-dose hormone therapy for perimenopausal and early menopausal symptoms, not merely as contraception. 1

• Combined oral contraceptives effectively manage genitourinary syndrome of menopause (GSM)—including vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs—by promoting epithelial thickening and vaginal secretion production. 2

• Perimenopausal women using COCs experience significant reductions in menstrual irregularity, heavy menstrual bleeding, and vasomotor symptoms (hot flashes), all of which improve quality of life. 3, 4

• The norethindrone acetate/ethinyl estradiol combination in Lo Loestrin Fe has been shown to reduce hot flash frequency by 75–84% within 4 weeks, with dose-dependent improvements in symptom severity. 5

• Continuous combined COC regimens (like Lo Loestrin Fe) provide endometrial protection, reduce bone turnover, and increase vertebral trabecular bone density—benefits that would be lost upon discontinuation. 6

---

Contraception Is No Longer the Primary Indication

Sterilization Does Not Eliminate Therapeutic Need

• While male sterilization (vasectomy) is highly effective contraception (failure rate ~0.15% after confirmation of azoospermia), this does not negate the hormone therapy benefits your patient derives from Lo Loestrin Fe. 7

• Age alone is not a contraindication to COC use; the CDC Medical Eligibility Criteria do not list age as a barrier, and women may continue COCs until age 50–55 if no medical contraindications exist. 3, 8

• The decision to continue or discontinue COCs in perimenopausal women should be based on symptom control, medical eligibility, and patient preference—not solely on contraceptive need. 4, 8

---

What You Should Do Instead

Assess Medical Eligibility and Symptom Control

1. Confirm absence of absolute contraindications to combined hormonal contraception:

   • History of venous thromboembolism, stroke, or coronary artery disease
   • Active or history of breast cancer or other estrogen-sensitive malignancy
   • Active liver disease
   • Uncontrolled hypertension (≥160/100 mmHg)
   • Migraine with aura (if age ≥35 years)
   • Current smoking (if age ≥35 years and smoking ≥15 cigarettes/day)
   • Thrombophilic disorders 7

2. Evaluate whether Lo Loestrin Fe is adequately controlling her genitourinary symptoms:

   • If symptoms persist despite COC use, consider adding low-dose vaginal estrogen (e.g., estradiol vaginal ring, cream, or suppository) for targeted local therapy without increasing systemic exposure. 9, 2
   • If vasomotor symptoms are inadequately controlled, consider switching to a higher-dose COC or transitioning to standard menopausal hormone therapy (MHT) with transdermal estradiol plus micronized progesterone. 9, 5

3. Discuss the option of transitioning from COC to MHT when appropriate:

   • Women typically transition from COCs to MHT around age 50–55 years or when menopausal status is confirmed (FSH >40 mIU/mL on two occasions ≥4 weeks apart while off hormonal contraception). 3, 4
   • Transdermal estradiol (50 mcg patch twice weekly) plus micronized progesterone (200 mg nightly for 12–14 days/month or continuously) is the preferred MHT regimen for women with an intact uterus, offering superior cardiovascular and breast safety compared to oral estrogen-progestin combinations. 9

---

Common Pitfalls to Avoid

• Do not discontinue Lo Loestrin Fe without first addressing the underlying genitourinary symptoms—this will leave your patient symptomatic and may worsen her quality of life. 2

• Do not assume that because contraception is no longer needed, hormone therapy is unnecessary—genitourinary syndrome of menopause requires ongoing estrogen therapy for symptom relief. 9, 2

• Do not switch directly to non-hormonal alternatives (e.g., SSRIs, gabapentin) for vasomotor symptoms without first optimizing hormonal therapy, as these are less effective than estrogen-based treatments. 10

• Do not initiate vaginal-only estrogen therapy (e.g., low-dose estriol) as monotherapy if she has systemic symptoms (hot flashes, night sweats)—vaginal estrogen addresses only local genitourinary symptoms and does not treat vasomotor symptoms. 9, 2

---

Algorithm for Decision-Making

Step 1: Confirm Medical Eligibility

• Screen for absolute contraindications to combined hormonal contraception (see list above). 7
• If contraindications exist, discontinue Lo Loestrin Fe and transition to alternative therapy (see Step 4).

Step 2: Assess Symptom Control

• If genitourinary symptoms are well-controlled on Lo Loestrin Fe:

  • Continue current regimen.
  • Reassess annually for ongoing symptom burden and development of contraindications. 9

• If genitourinary symptoms persist despite Lo Loestrin Fe:

  • Add low-dose vaginal estrogen (e.g., estradiol 10 mcg vaginal tablet twice weekly or estradiol vaginal ring 7.5 mcg/day) for targeted local therapy. 9, 2
  • Continue systemic COC for vasomotor symptom control and endometrial protection.

Step 3: Consider Transition to MHT (if age ≥50 years or confirmed menopause)

• Preferred regimen for women with intact uterus:

  • Transdermal estradiol 50 mcg patch applied twice weekly
  • Plus micronized progesterone 200 mg orally at bedtime for 12–14 days per 28-day cycle (sequential) or 100–200 mg nightly continuously (to eliminate withdrawal bleeding). 9

• For women post-hysterectomy:

  • Transdermal estradiol 50 mcg patch twice weekly alone (no progestin needed). 9

Step 4: If Hormonal Therapy Is Contraindicated

• For vasomotor symptoms:

  • Selective serotonin reuptake inhibitors (e.g., paroxetine 7.5 mg, escitalopram 10–20 mg) or serotonin-norepinephrine reuptake inhibitors (e.g., venlafaxine 75 mg). 10
  • Gabapentin 300–900 mg daily or pregabalin 75–150 mg twice daily. 10
  • Fezolinetant 45 mg daily (neurokinin-3 receptor antagonist)—monitor liver function tests. 10

• For genitourinary symptoms:

  • Vaginal moisturizers (e.g., hyaluronic acid-based products) applied 2–3 times weekly. 2
  • Vaginal lubricants (water- or silicone-based) used during sexual activity. 2
  • Ospemifene 60 mg daily (selective estrogen receptor modulator) if vaginal estrogen is contraindicated. 10, 2
  • Pelvic floor physical therapy for dyspareunia or pelvic floor hypertonicity. 2

---

Key Counseling Points

• Explain that Lo Loestrin Fe is currently serving as hormone therapy for her menopausal symptoms, not just contraception, and that discontinuing it will likely worsen her genitourinary symptoms. 3, 2

• Reassure her that continuing COCs in the perimenopausal period is safe if she has no contraindications, and that age alone is not a reason to stop. 3, 8

• Discuss the option of transitioning to standard MHT (transdermal estradiol + micronized progesterone) when she reaches confirmed menopause, as this regimen has a more favorable long-term safety profile than COCs. 9, 4

• If she prefers to discontinue hormonal therapy entirely, counsel her on the expected return of genitourinary symptoms and offer non-hormonal alternatives (vaginal moisturizers, lubricants, SSRIs for hot flashes). 10, 2